Get started
Author

Sergio Sandiego

Observed names: S Sandiego, S. Sandiego, Sandiego, Sergio
ORCID: 0009-0005-1810-7804
Observed ORCID: 0009-0005-1810-7804
OpenAlex ID: A5082623588
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
2023 · H. Borghaei, F. de Marinis, et al. · Annals of Oncology · 110
PDF
Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
2017 · Carmen Herrero-Vicent, Angel Guerrera, et al. · ecancermedicalscience · 32
PDF
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
2024 · Ander Puyalto, María Rodríguez-Remírez, et al. · Molecular Cancer · 22
PDF
Liquid biopsy for monitoring minimal residual disease in localized and locally-advanced non-small cell lung cancer after radical-intent treatment
2024 · Héctor Aguilar, Belén López-Roldán, et al. · The Journal of Liquid Biopsy · 13
PDF
Advanced systemic amyloidosis secondary to metastatic renal cell carcinoma
2020 · Maria Asunción Algarra, Maria José Juan Fita, et al. · ecancermedicalscience · 11
PDF
A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.
2021 · Virginia Calvo, Manuel Domine, et al. · Journal of Clinical Oncology · 9
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
2023 · Ander Puyalto, María Rodríguez-Remírez, et al. · Frontiers in Immunology · 6
PDF
PL03.10 Adjuvant Chemotherapy (CT) vs CT-immunotherapy for R0 Stage IB-IIIA NSCLC Patients (NADIM ADJUVANT): a Randomized, Phase 3 Trial
2025 · M. Provencio, R. Bernabé, et al. · Journal of Thoracic Oncology · 5
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain
2025 · Mariano Provencio, Manuel Cobo, et al. · The Lancet Regional Health - Europe · 4
Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year
2016 · Carmen Herrero-Vicent, Isidro Machado, et al. · ecancermedicalscience · 4
PDF
Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastastic head and neck squamous cell (PR R/M HNSCC) patients (pts): Real-life experience
2018 · G. Bruixola, J. Caballero Daroqui, et al. · Annals of Oncology · 1
P2.08.37 Neoadjuvant Chemoimmunotherapy in Resectable NSCLC. Real-World Evidence From a Spanish Multicenter Cohort
2025 · K. Medina Sanchez, C. Cabrera, et al. · Journal of Thoracic Oncology
Abstract P3-14-09: Hyperglycemia secondary to everolimus is associated with a prognosis improvement in hormone-sensitive metastatic breast cancer. A retrospective analysis
2019 · S Sandiego, MA Algarra, et al. · Cancer Research
Abstract P2-09-27: Integrated analysis of PTEN protein expression and PI3KCA mutations as predictors for pathological complete response in HER2-positive breast cancer
2018 · J Gavila, F Gozalbo, et al. · Cancer Research
Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT)
2017 · M.A. Climent Duran, B. Mellado, et al. · Annals of Oncology
PDF
Palliative sedation and oncological active treatment at the end of life; Is there any difference between the hospital and at home?
2017 · Carmen Herrero-Vicent, Sara García-Agudo, et al. · Cancer Reports and Reviews
PDF
Prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancers (TNBC) treated with neoadjuvant chemotherapy (NAC)
2016 · C. Herrero-Vicent, A. Guerrero, et al. · Annals of Oncology
Erratum: Diagnostic and therapeutic update of mantle cell lymphoma
2016 · Carmen Herrero-Vicent, Isidro Machado, et al. · ecancermedicalscience
PDF
Works count: 21
Citation count: 217
H-index: 6
I10-index: 5
Year
Topic
Type